InsiderTrades

Form 4 for JBIO Jade Biosciences, Inc.

Accepted 2021-07-06 00:00:00 ET · period of report 2021-07-01 · accession 0001104659-21-089435 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2021-07-06 2021-07-02 JBIO GRAYZEL DAVID S. Dir C - Cnv Deriv — +2.57M 2.57M New —
DI 2021-07-06 2021-07-02 JBIO GRAYZEL DAVID S. Dir P - Purchase $14.00 +535.7K 3.10M +21% +$7.50M
D 2021-07-06 2021-07-01 JBIO GRAYZEL DAVID S. Dir A - Grant $11.15 +2,153 2,153 New +$24.0K
DI 2021-07-06 2021-07-02 JBIO GRAYZEL DAVID S. Dir C - Cnv Deriv — -7.98M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-02 C A 2,568,165 — 2,568,165 I By Atlas Venture Fund XII, L.P. — — (F1) Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. (F2) The shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Fund XII"). The general partner of Atlas Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP.. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by Atlas Fund XII, except to the extent of his pecuniary interest therein, if any.
2 Common Common Stock 2021-07-02 P A 535,714 $14.00 3,103,879 I By Atlas Venture Fund XII, L.P. — — (F2) The shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Fund XII"). The general partner of Atlas Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP.. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by Atlas Fund XII, except to the extent of his pecuniary interest therein, if any.
3 Derivative Stock Option (Right to Buy) 2021-07-01 A A 2,153 $11.15 2,153 D By Atlas Venture Fund XII, L.P. $19.41 · — to 2031-06-30 2,153 Common Stock (F2) The shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Fund XII"). The general partner of Atlas Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP.. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by Atlas Fund XII, except to the extent of his pecuniary interest therein, if any. (F3) This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021.
4 Derivative Series A Preferred Stock 2021-07-02 C D 7,976,754 — 0 I — · — to — 2,568,165 Common Stock (F1) Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.